Healthpeak Properties, Inc.

Report azionario NYSE:DOC

Capitalizzazione di mercato: US$13.7b

Healthpeak Properties Crescita futura

Criteri Future verificati 0/6

Si prevede che gli utili di Healthpeak Properties diminuiranno a 7.2% all'anno, mentre si prevede che i suoi ricavi annuali cresceranno a 4.3% all'anno. Si prevede che l'EPS diminuirà di 4.4% all'anno. Si prevede che il ritorno sul capitale proprio sarà 2.2% in 3 anni.

Informazioni chiave

-7.2%

Tasso di crescita degli utili

-4.37%

Tasso di crescita dell'EPS

Health Care REITs crescita degli utili25.3%
Tasso di crescita dei ricavi4.3%
Rendimento futuro del capitale proprio2.18%
Copertura analitica

Good

Ultimo aggiornamento16 Jun 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Seeking Alpha • Jun 19

Healthpeak Properties: This 6% Yielding REIT Has More Room To Run

Summary Healthpeak Properties remains a Strong Buy, combining value, income, and recovery potential in healthcare real estate. DOC’s outpatient medical and life sciences segments show improving occupancy, strong lease spreads, and embedded rent escalators supporting steady growth. The Janus Living spin-off unlocks value in senior housing, with DOC retaining 82% ownership and benefiting from high segment growth. DOC offers a 6.2% yield, BBB+ balance sheet, and trades at 11.2x forward P/FFO, well below its historical average. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Jun 12

DOC: Raised 2026 Outlook And Buybacks Will Conceal Mounting Margin Risks

Analysts have adjusted their price target on Healthpeak Properties from $16.00 to $17.00, tying the change to updated assumptions around discount rates, revenue trends, profit margins, and future P/E expectations. What's in the News Healthpeak Properties reported first quarter 2026 funds from operations as adjusted (FFOA) of $0.45 per share, which was above analyst estimates, supported by steady leasing momentum.
Aggiornamento della narrazione • May 29

DOC: Buybacks And Higher Earnings Guidance Will Support Measured Future Upside Potential

Analysts have nudged their price target for Healthpeak Properties from about $20.17 to roughly $20.83, reflecting updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Healthpeak Properties reported repurchasing 5,950,000 shares for US$100 million between January 1, 2026 and May 5, 2026, representing 0.86% of its shares under the ongoing buyback program announced on July 25, 2024 (Key Developments).
Aggiornamento della narrazione • May 13

DOC: Buyback Activity And Raised Earnings Outlook Will Mask Weaker Margin Outlook

Analysts have kept their $16.00 price target on Healthpeak Properties unchanged, citing updated assumptions that include a slightly higher discount rate, a shift to declining revenue growth, lower profit margins, and a much higher future P/E estimate. What's in the News From January 1, 2026 to May 5, 2026, Healthpeak Properties repurchased 5,950,000 shares, representing 0.86% of its stock for US$100 million under its existing buyback program (Key Developments).
Aggiornamento della narrazione • Apr 28

DOC: Higher Margins And Earnings Outlook Will Support Future Upside Potential

Analysts have trimmed their price target on Healthpeak Properties by about $0.64 to $25.80 as updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E are incorporated into their models. What's in the News Healthpeak Properties reported that from October 1, 2025 to December 31, 2025, it repurchased 0 shares for $0 million under its existing buyback program, closing out a total repurchase of 5,091,156 shares, or 0.73%, for $94.17 million under the authorization announced on July 25, 2024 (Key Developments).
Aggiornamento della narrazione • Apr 14

DOC: Share Repurchases And Improved Margins Will Support Future Upside Potential

Analysts have slightly raised their price target on Healthpeak Properties to about $26.44, a marginal change from roughly $26.43. The revision reflects updated assumptions related to discount rate, revenue growth, profit margin and a projected future P/E near 98x.
Aggiornamento della narrazione • Mar 31

DOC: Earnings Guidance And Completed Buyback Will Shape Measured Future Return Potential

Analysts now hold their $16.00 price target on Healthpeak Properties while adjusting underlying assumptions slightly on discount rate, revenue growth, profit margin, and future P/E. This reflects fine tuning rather than a major shift in their view of the stock.
Aggiornamento della narrazione • Mar 16

DOC: Share Repurchases And Stronger Margins Will Support Future Upside Potential

Analysts now estimate Healthpeak Properties' fair value price target at about $26.43, compared with the previous estimate of roughly $26.71. The revision reflects updated views on revenue growth, profit margin and future P/E assumptions.
Aggiornamento della narrazione • Mar 02

DOC: Earnings Outlook And Completed Buyback Will Highlight Limited Future Upside

Analysts have maintained their $16.00 price target for Healthpeak Properties. They cite only small adjustments to assumptions around discount rate, revenue growth, profit margin, and future P/E that together do not materially change their view of the stock’s valuation.
Aggiornamento della narrazione • Feb 16

DOC: Share Buyback Completion And Earnings Outlook Will Shape Fair Prospects

Analysts have adjusted their price target on Healthpeak Properties from $18.00 to $16.00. The revision reflects updated models that incorporate a slightly higher discount rate, a lower profit margin assumption and a revised future P/E estimate, while also taking into account a higher revenue growth outlook.
Aggiornamento della narrazione • Feb 02

DOC: Stable Margins And Modest Assumption Shifts Will Support Future Upside Potential

Analysts now estimate fair value for Healthpeak Properties at about US$20.17 per share, compared with roughly US$20.68 previously. The change reflects slightly revised assumptions around discount rates, long term revenue growth, profit margins and future P/E levels.
Aggiornamento della narrazione • Jan 19

DOC: Share Repurchases And Higher Future P/E Will Support Upside Potential

Analysts have nudged their price target on Healthpeak Properties slightly higher to about US$26.71 from roughly US$26.65, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple. Together, these factors shape a modestly revised outlook for the shares.
Aggiornamento della narrazione • Jan 05

DOC: Completed Buyback And Stable Margins Will Support Future Upside Potential

Analysts have trimmed their price target on Healthpeak Properties to about US$20.68 per share from roughly US$20.92, citing slightly higher discount rate assumptions along with modest adjustments to revenue growth, profit margin, and future P/E inputs in their models. What's in the News From July 1, 2025 to September 30, 2025, Healthpeak Properties reported no share repurchases under its current program, with 0 shares bought for US$0 million in that period (Key Developments).
Aggiornamento della narrazione • Dec 14

DOC: Share Repurchases And Margin Outlook Will Support Future Upside Potential

Analysts have trimmed their price target on Healthpeak Properties to approximately $26.65 from about $27.73, reflecting slightly higher discount-rate assumptions and more modest revenue growth expectations, partially offset by improved profit margin and a lower projected future price to earnings multiple. What's in the News Completed repurchase of 5,091,156 shares for approximately $94.17 million under the buyback program announced on July 25, 2024, representing about 0.73% of shares (Key Developments) No additional shares were repurchased between July 1, 2025 and September 30, 2025 under the existing buyback tranche, with total spending of $0 million in the period (Key Developments) Removed from the FTSE All-World Index (USD), which may affect index-linked ownership and trading volumes for the stock (Key Developments) Valuation Changes Fair Value Estimate decreased slightly to approximately $26.65 from about $27.73.
Aggiornamento della narrazione • Nov 30

DOC: Lower Discount Rate Will Support Improving Profit Margins Moving Forward

Analysts have modestly increased their price target for Healthpeak Properties from $20.86 to $20.92. This reflects slightly improved forward-looking profit margins and a lower discount rate, although it is partially tempered by a more conservative outlook for revenue growth.
Aggiornamento della narrazione • Nov 16

DOC: Discount Rate Improvements Will Drive Margin Gains Ahead

Analysts have slightly lowered their price target for Healthpeak Properties from $21.03 to $20.86. They cite modest adjustments in growth and discount rate assumptions, while also noting a marginal improvement in profit margins.
Aggiornamento della narrazione • Nov 01

DOC: Share Repurchase And Index Removal Will Unlock Future Upside Potential

Analysts have slightly lowered their price target for Healthpeak Properties to $21.03 from $21.19, citing modest reductions in revenue growth and profit margin expectations as key factors behind the revision. What's in the News Healthpeak Properties completed the repurchase of 5,091,156 shares, representing 0.73% of outstanding shares, for $94.17 million under its buyback announced on July 25, 2024 (Key Developments).
Aggiornamento della narrazione • Oct 17

Outpatient And Life Science Trends Will Create Future Opportunities

Analysts have slightly lowered their price target for Healthpeak Properties from $21.31 to $21.19, citing a modest increase in expected discount rates and revenue growth, along with a small dip in projected profit margin. What's in the News Healthpeak Properties, Inc.
Aggiornamento della narrazione • Oct 03

Outpatient And Life Science Trends Will Create Future Opportunities

Analysts have slightly revised their price target for Healthpeak Properties downward from $21.38 to $21.31. This change reflects minor updates to discount rate and valuation assumptions.
Aggiornamento della narrazione • Sep 17

Outpatient And Life Science Trends Will Create Future Opportunities

Healthpeak Properties' fair value estimate edged only slightly lower as both its future P/E ratio and net profit margin saw negligible declines, resulting in a marginal decrease in the consensus analyst price target from $21.53 to $21.38. What's in the News Lowered full-year 2025 diluted EPS guidance to $0.25–$0.31 from $0.30–$0.36.
Aggiornamento della narrazione • Sep 02

Outpatient And Life Science Trends Will Create Future Opportunities

The slight reduction in Healthpeak Properties’ future P/E ratio suggests a modestly improved earnings outlook relative to price, but with consensus revenue growth unchanged, analysts have only marginally decreased the fair value estimate from $21.72 to $21.53. What's in the News Healthpeak Properties lowered its full-year 2025 diluted EPS guidance to $0.25 – $0.31 from $0.30 – $0.36.
Aggiornamento della narrazione • Aug 19

Outpatient And Life Science Trends Will Create Future Opportunities

Healthpeak Properties’ fair value saw a marginal decrease as a slight drop in its future P/E multiple reflected modestly softer forward expectations. What's in the News Completed share repurchase program, buying 5,091,156 shares (0.73%) for $94.17 million.
Seeking Alpha • Apr 10

Healthpeak Properties: Defensive REIT With Strong Dividend And Post-Merger Upside

Summary Healthpeak Properties is a high-quality healthcare REIT trading at a low valuation, offering 25-30% price appreciation and a ~6.7% annual dividend yield. The successful merger with Physicians Realty Trust has created a dominant healthcare REIT with significant synergies, improving operational performance and tenant diversification. Healthpeak's portfolio benefits from a strong demographic tailwind, robust leasing activity, and strategic focus on outpatient medical buildings and life science properties. Trading at a lower valuation than peers, Healthpeak's strong fundamentals make it an attractive buy for total return and income-focused investors. Read the full article on Seeking Alpha
Seeking Alpha • Mar 13

Why Healthpeak Is A Smart Buy For Income Investors

Summary Healthpeak Properties offers a compelling investment opportunity with a 5.9% dividend yield, strong operating fundamentals, and an attractive valuation. DOC's diversified healthcare portfolio benefits from limited new supply, robust demand, and strategic loan investments in life sciences for immediate earnings accretion. With a strong balance sheet and a forward P/FFO of 11.2, DOC is well-positioned for long-term growth and potential market-beating returns. Read the full article on Seeking Alpha
Seeking Alpha • Jan 06

A REIT Geek Who Likes Healthpeak

Summary Healthpeak Properties is a top healthcare REIT with a robust portfolio, strong fundamentals, and a well-covered 6% yield, making it an attractive investment. Despite recent price declines, Healthpeak's AFFO growth, low leverage, and strategic life-science assets position it for stability and modest growth. The lab space market's tightening supply and increased biotech capital raise Healthpeak's valuation potential, justifying a conservative P/AFFO of 14-16x. At a share price of $16-$18, Healthpeak offers a compelling buy opportunity with an expected annualized return of 16-17%, supported by analyst consensus. Read the full article on Seeking Alpha
Seeking Alpha • Dec 22

Healthpeak Properties: I'm Buying The 6% Dividend Yield

Summary Healthpeak Properties has dipped and now offers a 6% dividend yield that's 147% covered by its fiscal 2024 third-quarter FFO. The REIT generated free cash flow in excess of dividend payments during the third quarter. Spiking US 10-year Treasury yield forms a material headwind for stock price growth. Read the full article on Seeking Alpha
Seeking Alpha • Oct 21

Healthpeak: Potential Upside Still Exists, But Don't Expect Much

Summary Healthpeak Properties is a BBB+ rated healthcare REIT with a solid portfolio, low leverage, and a well-covered 5.4% yield, offering a conservative 15% annualized return. The company is nearing full valuation but remains attractive due to its stable fundamentals, slight growth prospects, and recent merger benefits. Despite low growth estimates, Healthpeak's conservative P/AFFO of 14.25x suggests a potential upside, making it a "Buy" with a $27/share price target. Healthpeak fulfills all my investment criteria except being cheap, making it a sound investment for conservative, double-digit returns. Read the full article on Seeking Alpha
User avatar
Nuova narrazione • Aug 21

Strategic Mergers And Key Life Science Leases Propel Revenue And Earnings Growth

Execution of priorities like merger integration and asset sales directly boosts 2024 guidance, signaling positive revenue and earnings impact.
Seeking Alpha • Jul 18

Healthpeak: Missing The Boat Above $20/Share

Summary I update on investment in Healthpeak REIT, owning a significant stake with a positive return on investment and yield of over 7%. I highlight the undervaluation of Healthpeak, positive outlook on a diverse portfolio, and caution on current share price above $20. I maintain my thesis on Healthpeak as an attractive buy with conservative double-digit upside potential, based on sound fundamentals and future growth prospects. Read the full article on Seeking Alpha
Seeking Alpha • Jul 09

Healthpeak Properties: A 6.1% Yielding Healthcare Trust With Upside

Summary Healthpeak Properties is a leading U.S. real estate investment trust focused on medical office buildings, poised for long-term growth. The merger with Physician Realty Trust has increased the trust's portfolio to 748 properties, with potential for $80 million in synergies. With a steady dividend and strong funds from operations growth, Healthpeak Properties is a compelling investment for passive income investors. Read the full article on Seeking Alpha
Seeking Alpha • May 14

Healthpeak Q1 - The "Best" In The Space With A 15% Upside

Summary Healthpeak (DOC) is an attractive healthcare REIT with a diverse portfolio and a yield of over 7%. The company is unlikely to see significant near-term AFFO growth, but offers stability and potential slight growth. The stock is currently undervalued and has a conservative double-digit upside, making it a good buy. Read the full article on Seeking Alpha
Seeking Alpha • Apr 12

HealthPeak Properties: A Quality Healthcare REIT That Should Get Back To Dividend Growth

Summary HealthPeak Properties recently closed on its merger with Physicians Realty Trust, which is expected to generate merger-related synergies and be accretive to AFFO. The company reported strong earnings with solid growth in same-store NOI and AFFO. HealthPeak Properties has a strong balance sheet and attractive valuation below peers and the sector median, offering dividend investors a good buying opportunity. Due to the recent merger, I expect the REIT to get back to dividend growth in the near future. The share price may continue to experience volatility due to shrinking sentiment surrounding interest rate cuts in June. Read the full article on Seeking Alpha

Previsioni di crescita degli utili e dei ricavi

NYSE:DOC - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20283,058151N/A1,3945
12/31/20272,904127N/A1,30510
12/31/20262,805199N/A1,36910
3/31/20262,8732221,2331,233N/A
12/31/20252,823711,2521,252N/A
9/30/20252,801-391,2411,241N/A
6/30/20252,7961641,2451,245N/A
3/31/20252,7972781,1971,197N/A
12/31/20242,7002421,0701,070N/A
9/30/20242,5563091,0181,018N/A
6/30/20242,412287953953N/A
3/31/20242,262193935935N/A
12/31/20232,181304956956N/A
9/30/20232,152239932932N/A
6/30/20232,116530922922N/A
3/31/20232,088543880880N/A
12/31/20222,061495900900N/A
9/30/20222,020514917917N/A
6/30/20221,981213885885N/A
3/31/20221,939312867867N/A
12/31/20211,896117795795N/A
9/30/20211,84568790790N/A
6/30/20211,787-17798798N/A
3/31/20211,719-125786786N/A
12/31/20201,645144758758N/A
9/30/2020988326757757N/A
6/30/20201,102311785785N/A
3/31/20201,185240783783N/A
12/31/20191,240159N/A846N/A
9/30/20191,908831N/A844N/A
6/30/20191,826976N/A790N/A
3/31/20191,8041,080N/A811N/A
12/31/20181,191822N/A849N/A
9/30/20181,848169N/A842N/A
6/30/20181,84662N/A855N/A
3/31/20181,835-8N/A850N/A
12/31/20171,848413N/A847N/A
9/30/20171,945549N/A853N/A
6/30/20172,022599N/A979N/A
3/31/20172,101774N/A1,139N/A
12/31/20162,129361N/A1,214N/A
9/30/20161,655384N/A1,353N/A
6/30/20161,781456N/A1,295N/A
3/31/20161,850427N/A1,261N/A
12/31/20151,940139N/A1,216N/A
9/30/20152,478235N/A1,233N/A
6/30/20152,418367N/A1,235N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che gli utili di DOC diminuiranno nei prossimi 3 anni ( -7.2% all'anno).

Guadagni vs Mercato: Si prevede che gli utili di DOC diminuiranno nei prossimi 3 anni ( -7.2% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di DOC diminuiranno nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di DOC ( 4.3% all'anno) crescerà più lentamente rispetto al mercato US ( 13% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di DOC ( 4.3% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di DOC sarà basso tra 3 anni ( 2.2 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/06/22 15:40
Prezzo dell'azione a fine giornata2026/06/18 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Healthpeak Properties, Inc. è coperta da 36 analisti. 10 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Jacob KilsteinArgus Research Company
David RodgersBaird
Adam FeinsteinBarclays